Clinical trials: Genital Neoplasms
Tobacco Use Cessation
Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study
The goal of this research study is to learn about 2 different interactive methods that are designed to help people with HIV/AIDS stop smoking.
- Trial name
- NCT02302859
- Testing
- Nicotine Patch, Questionnaires, Pamphlet
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Prostate Cancer
Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
This phase II trial studies how well fluorine F 18 sodium fluoride positron emission tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging (MRI) work in finding metastases in patients with…
- Trial name
- NCT01967862
- Testing
- computed tomography, bone scan, 3-Tesla magnetic resonance imaging
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Cancer of Prostate
De-implementation of Low Value Castration for Men With Prostate Cancer
This study will use a theory-based, mixed methods approach to identify, tailor and pilot two different de-implementation strategies that vary widely in delivery, impact, and expected results for reducing low value androgen…
- Trial name
- DeADT (NCT03579680)
- Testing
- ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Cervical Cancer
Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer
The purpose of this study is to find out whether patients with cervical cancer treated with PET-guided Bone Marrow Sparing IMRT have less side effects with equal cancer control compared to standard radiation techniques (IMRT).
- Trial name
- NCT01554397
- Testing
- PET-guided Bone Marrow-Sparing Intensity Modulated Radiation Therapy (IMRT), Cisplatin, IMRT
- Where
- 7 sites in United States, China and 4 more
- Volunteers
- 101 people
- Sponsor
- University of California, San Diego
Prostate Cancer
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00471718
- Testing
- ABT-751
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Prostate Cancer
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, efficacy and safety of CAM2032 versus Eligard, in patients with prostate cancer.
- Trial name
- NCT02212197
- Testing
- leuprolide acetate FluidCrystal® injection depot, leuprolide acetate
- Where
- 7 sites in Finland, Hungary
- Volunteers
- 51 people
- Sponsor
- Camurus AB
Cancer, Solid Tumor
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and…
- Conditions
- Cancer, Solid Tumor, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT05708924
- Testing
- FT538, Enoblituzumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Breast Cancer
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Background: All cells go through cycles which allow them to divide. In normal cells, checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) (CHEK 2 (Chk1/2) stop cell division at various points to allow any damage to…
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02203513
- Testing
- LY2606368
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Phase II single arm, open label, nonrandomized study. The aim of our study is to assess the Progression Free Survival (PFS) in suboptimally cytoreduced epithelial ovarian/ primary peritoneal/ fallopian tube cancer patients…
- Trial name
- NCT02766582
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Medical College of Wisconsin
Prostate Cancer
Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
There is an increasing number of reports describing the existence of a proportion of prostate cancer patients who present with a reduced number of metastases (<5 lesions) at relapse.
- Trial name
- OLIGOPELVIS (NCT02274779)
- Testing
- ELIGARD
- Where
- 2 sites in France
- Volunteers
- 74 people
- Sponsor
- Institut Cancerologie de l'Ouest
Penile Cancer
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
- Trial name
- NCT00512096
- Testing
- Ifosfamide, Paclitaxel (Taxol), Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Genistein in Treating Patients With Prostate Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT01126879
- Testing
- genistein, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Cervical Cancer
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.
- Trial name
- NCT02172911
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inovio Pharmaceuticals
Prostate Cancer
Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Radical prostatectomy provides potentially curative removal of the cancer. However, it subjects patients to the morbidity and mortality of the surgery and may be neither necessary nor effective.
- Trial name
- PIVOT (NCT00007644)
- Testing
- Radical prostatectomy
- Where
- 31 sites in United States
- Volunteers
- 731 people
- Sponsor
- VA Office of Research and Development
Cervical Cancer
BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of the investigational drug in combination with radiation to learn whether the drug(s) works in treating a specific…
- Trial name
- NCT03527264
- Testing
- Nivolumab induction, Cisplatin, Radiation
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Brown University
Prostate Cancer
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
The purpose of this study is to evaluate the effectiveness, safety and tolerability of nivolumab followed by ipilimumab, in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- CheckMate 650 (NCT02985957)
- Testing
- Nivolumab, Ipilimumab, Cabazitaxel
- Where
- 59 sites in United States, Australia and 8 more
- Volunteers
- 351 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Background: No treatment is known to improve survival for prostate cancer patients who have not been helped by previous treatments with hormones and chemotherapy.
- Trial name
- NCT00450619
- Testing
- Samarium Sm 153 lexidronam pentasodium, Sargramostim, Recombinant vaccinia-TRICOM vaccine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Men with progressive metastatic Castration-Resistant Prostate Cancer post first-line treatment with either androgen deprivation therapy alone or androgen deprivation therapy plus docetaxel who have an identified related female…
- Trial name
- NCT02995330
- Testing
- Bone marrow transplantation, Cytoxan, testosterone cypionate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Cancer
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00691301
- Testing
- cisplatin, pemetrexed disodium
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Prostate Cancer
Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy
The purpose of this study is to determine whether treatment with Zactima for up to 18 months will prolong the off-treatment interval in patients who are undergoing intermittent androgen deprivation therapy.
- Trial name
- ZENITH (NCT00686036)
- Testing
- vandetanib
- Where
- 11 sites in Canada
- Volunteers
- 17 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.